Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
612 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015', provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Head And Neck Cancer Squamous Cell Carcinoma Overview 12 Therapeutics Development 13 Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview 13 Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis 14 Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies 15 Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 22 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance 23 Late Stage Products 23 Clinical Stage Products 24 Early Stage Products 25 Unknown Stage Products 26 Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies 27 Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes 35 Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 36 AB Science SA 36 AbbVie Inc. 37 Acceleron Pharma, Inc. 38 Altor BioScience Corporation 39 Amgen Inc. 40 Ascenta Therapeutics, Inc. 41 Astex Pharmaceuticals, Inc. 42 AstraZeneca Plc 43 AVEO Pharmaceuticals, Inc. 44 BIND Therapeutics, Inc. 45 Bionovis SA 46 Boehringer Ingelheim GmbH 47 Bristol-Myers Squibb Company 48 CEL-SCI Corporation 49 Cellceutix Corporation 50 Celldex Therapeutics, Inc. 51 Celltrion, Inc. 52 Centrose LLC 53 Critical Outcome Technologies Inc. 54 Daiichi Sankyo Company, Limited 55 Eisai Co., Ltd. 56 Eli Lilly and Company 57 Etubics Corporation 58 F. Hoffmann-La Roche Ltd. 59 G&E Herbal Biotechnology Co., Ltd. 60 Genentech, Inc. 61 Genexine, Inc. 62 Genzyme Corporation 63 GlaxoSmithKline Plc 64 Gliknik, Inc. 65 Glycotope GmbH 66 Hanmi Pharmaceuticals, Co. Ltd. 67 ImmunoGen, Inc. 68 Immunomedics, Inc. 69 Immunovative Therapies, Ltd. 70 Incyte Corporation 71 Innate Pharma SA 72 Inovio Pharmaceuticals, Inc. 73 Karyopharm Therapeutics, Inc. 74 Laboratoires Pierre Fabre SA 75 Loxo Oncology, Inc. 76 Mabion SA 77 MacroGenics, Inc. 78 MedImmune, LLC 79 Merck & Co., Inc. 80 Merck KGaA 81 Mirati Therapeutics Inc. 82 Molplex Ltd. 83 Novartis AG 84 Oncobiologics, Inc. 85 Oncolytics Biotech Inc. 86 Onconova Therapeutics, Inc. 87 OncoSec Medical Inc. 88 Ono Pharmaceutical Co., Ltd. 89 OXiGENE, Inc. 90 Panacea Biotec Limited 91 PCI Biotech AS 92 Pfizer Inc. 93 Shanghai Henlius Biotech Co., Ltd. 94 Shenzen SiBiono GeneTech Co., Ltd 95 Shionogi & Co., Ltd. 96 Sillajen Biotherapeutics 97 Sorrento Therapeutics, Inc. 98 Symphogen A/S 99 Synta Pharmaceuticals Corp. 100 Takara Bio Inc. 101 Threshold Pharmaceuticals, Inc. 102 VasGene Therapeutics, Inc. 103 VentiRx Pharmaceuticals, Inc. 104 Virttu Biologics Limited 105 Viventia Bio Inc. 106 Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 107 Assessment by Monotherapy Products 107 Assessment by Combination Products 108 Assessment by Target 109 Assessment by Mechanism of Action 115 Assessment by Route of Administration 120 Assessment by Molecule Type 122 Drug Profiles 124 ABBV-221 - Drug Profile 124 AdIL-24 - Drug Profile 125 afatinib dimaleate - Drug Profile 127 AlloVax - Drug Profile 132 alpelisib - Drug Profile 134 ALT-803 - Drug Profile 136 AMG-319 - Drug Profile 139 Antibodies to Inhibit FRMD4A for Oncology - Drug Profile 140 Antisense Oligonucleotide to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 141 AT-406 - Drug Profile 142 AV-203 - Drug Profile 145 avelumab - Drug Profile 146 AZD-6738 - Drug Profile 148 AZD-9150 - Drug Profile 150 bleomycin sulfate - Drug Profile 151 BMS-986016 - Drug Profile 154 BNV-003 - Drug Profile 155 buparlisib hydrochloride - Drug Profile 156 capmatinib - Drug Profile 160 Cellular Immunotherapy for Oncology - Drug Profile 163 Cellular Immunotherapy to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 165 cetuximab - Drug Profile 166 cetuximab biobetter - Drug Profile 173 cetuximab biosimilar - Drug Profile 174 cetuximab biosimilar - Drug Profile 175 cetuximab biosimilar - Drug Profile 176 cetuximab biosimilar - Drug Profile 177 cetuximab biosimilar - Drug Profile 179 cetuximab biosimilar - Drug Profile 180 COTI-2 - Drug Profile 181 dalantercept - Drug Profile 184 DNA IL-12 - Drug Profile 186 docetaxel - Drug Profile 189 DPV-001 - Drug Profile 192 DTP-348 - Drug Profile 194 duligotuzumab - Drug Profile 196 durvalumab - Drug Profile 198 durvalumab + tremelimumab - Drug Profile 202 E-7046 - Drug Profile 204 EDC-2 - Drug Profile 205 elgemtumab - Drug Profile 206 enoblituzumab - Drug Profile 208 epacadostat - Drug Profile 210 everolimus - Drug Profile 212 ficlatuzumab - Drug Profile 218 futuximab - Drug Profile 221 ganetespib - Drug Profile 223 gedatolisib - Drug Profile 228 Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile 230 Gene Therapy to Activate p53 for Oncology - Drug Profile 231 GL-0817 - Drug Profile 232 golvatinib tartrate - Drug Profile 234 GS-10 - Drug Profile 236 GSK-2636771 - Drug Profile 238 GSK-2849330 - Drug Profile 239 GSK-3174998 - Drug Profile 240 GX-051 - Drug Profile 241 HF-10 - Drug Profile 242 HSV-1716 - Drug Profile 244 IC-1001 - Drug Profile 247 IMGN-289 - Drug Profile 248 INO-3106 - Drug Profile 249 INO-3112 - Drug Profile 250 IPH-2201 - Drug Profile 251 JX-929 - Drug Profile 253 KGP-94 - Drug Profile 254 KM-3174 - Drug Profile 255 lenvatinib - Drug Profile 259 Leukocyte Interleukin - Drug Profile 265 LGK-974 - Drug Profile 268 lirilumab - Drug Profile 269 LOXO-101 - Drug Profile 271 lumretuzumab - Drug Profile 273 masitinib - Drug Profile 275 merestinib - Drug Profile 280 MGCD-265 - Drug Profile 281 Monoclonal Antibodies to Antagonize Frizzled Receptors for Breast Cancer and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 284 Monoclonal Antibody to Target CD147 for Pancreatic Adenocarcinoma and Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 285 motolimod - Drug Profile 286 MV-NIS - Drug Profile 288 nilotinib - Drug Profile 290 nimotuzumab - Drug Profile 293 nivolumab - Drug Profile 297 NP-001 - Drug Profile 305 olaparib - Drug Profile 306 onalespib - Drug Profile 310 Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 313 palbociclib - Drug Profile 315 panitumumab - Drug Profile 319 patritumab - Drug Profile 322 pelareorep - Drug Profile 324 pembrolizumab - Drug Profile 329 PF-04518600 - Drug Profile 338 poziotinib - Drug Profile 339 prexasertib - Drug Profile 341 Recombinant Peptide to Target EGFR for Oncology - Drug Profile 343 Recombinant Protein for Oncology - Drug Profile 344 rigosertib sodium - Drug Profile 345 S-488210 - Drug Profile 350 sacituzumab - Drug Profile 351 SB-01 - Drug Profile 353 selinexor - Drug Profile 355 Small Molecules for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 361 Small Molecules to Inhibit 16S rRNA for Head And Neck Cancer Squamous Cell Carcinoma and Oral Cancer - Drug Profile 362 Small Molecules to Inhibit CREB Protein for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 363 Small Molecules to Inhibit IL-6 for Head and Neck Squamous Cell Carcinoma - Drug Profile 364 Solarise - Drug Profile 365 tarloxotinib bromide - Drug Profile 366 trametinib dimethyl sulfoxide + uprosertib - Drug Profile 368 urelumab - Drug Profile 370 Vaccine for HPV Associated Head and Neck Squamous Cell Carcinoma - Drug Profile 372 vandetanib - Drug Profile 373 varlilumab - Drug Profile 379 Vas-01 - Drug Profile 381 VB-4847 - Drug Profile 383 vinflunine ditartrate - Drug Profile 385 Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates 387 Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects 585 Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products 589 Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones 591 Featured News & Press Releases 591 Appendix 603 Methodology 603 Coverage 603 Secondary Research 603 Primary Research 603 Expert Panel Validation 603 Contact Us 603 Disclaimer 604
List of Tables
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2015 21 Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2015 22 Number of Products under Development by Companies, H2 2015 24 Number of Products under Development by Companies, H2 2015 (Contd..1) 25 Number of Products under Development by Companies, H2 2015 (Contd..2) 26 Number of Products under Development by Companies, H2 2015 (Contd..3) 27 Number of Products under Development by Companies, H2 2015 (Contd..4) 28 Number of Products under Development by Companies, H2 2015 (Contd..5) 29 Number of Products under Investigation by Universities/Institutes, H2 2015 30 Comparative Analysis by Late Stage Development, H2 2015 31 Comparative Analysis by Clinical Stage Development, H2 2015 32 Comparative Analysis by Early Stage Development, H2 2015 33 Comparative Analysis by Unknown Stage Development, H2 2015 34 Products under Development by Companies, H2 2015 35 Products under Development by Companies, H2 2015 (Contd..1) 36 Products under Development by Companies, H2 2015 (Contd..2) 37 Products under Development by Companies, H2 2015 (Contd..3) 38 Products under Development by Companies, H2 2015 (Contd..4) 39 Products under Development by Companies, H2 2015 (Contd..5) 40 Products under Development by Companies, H2 2015 (Contd..6) 41 Products under Development by Companies, H2 2015 (Contd..7) 42 Products under Investigation by Universities/Institutes, H2 2015 43 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AB Science SA, H2 2015 44 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AbbVie Inc., H2 2015 45 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2015 46 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Altor BioScience Corporation, H2 2015 47 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H2 2015 48 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ascenta Therapeutics, Inc., H2 2015 49 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 50 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AstraZeneca Plc, H2 2015 51 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 52 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by BIND Therapeutics, Inc., H2 2015 53 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bionovis SA, H2 2015 54 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015 55 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2015 56 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CEL-SCI Corporation, H2 2015 57 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2015 58 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2015 59 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celltrion, Inc., H2 2015 60 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Centrose LLC, H2 2015 61 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Critical Outcome Technologies Inc., H2 2015 62 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 63 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2015 64 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2015 65 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Etubics Corporation, H2 2015 66 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 67 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2015 68 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genentech, Inc., H2 2015 69 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genexine, Inc., H2 2015 70 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genzyme Corporation, H2 2015 71 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2015 72 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Gliknik, Inc., H2 2015 73 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H2 2015 74 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015 75 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by ImmunoGen, Inc., H2 2015 76 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunomedics, Inc., H2 2015 77 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H2 2015 78 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Incyte Corporation, H2 2015 79 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Innate Pharma SA, H2 2015 80 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 81 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 82 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Laboratoires Pierre Fabre SA, H2 2015 83 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Loxo Oncology, Inc., H2 2015 84 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mabion SA, H2 2015 85 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MacroGenics, Inc., H2 2015 86 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune, LLC, H2 2015 87 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2015 88 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck KGaA, H2 2015 89 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mirati Therapeutics Inc., H2 2015 90 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molplex Ltd., H2 2015 91 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H2 2015 92 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2015 93 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H2 2015 94 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H2 2015 95 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OncoSec Medical Inc., H2 2015 96 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 97 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OXiGENE, Inc., H2 2015 98 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2015 99 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech AS, H2 2015 100 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Pfizer Inc., H2 2015 101 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2015 102 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shenzen SiBiono GeneTech Co., Ltd, H2 2015 103 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H2 2015 104 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2015 105 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sorrento Therapeutics, Inc., H2 2015 106 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Symphogen A/S, H2 2015 107 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Synta Pharmaceuticals Corp., H2 2015 108 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Takara Bio Inc., H2 2015 109 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 110 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VasGene Therapeutics, Inc., H2 2015 111 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2015 112 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Virttu Biologics Limited, H2 2015 113 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Viventia Bio Inc., H2 2015 114 Assessment by Monotherapy Products, H2 2015 115 Assessment by Combination Products, H2 2015 116 Number of Products by Stage and Target, H2 2015 118 Number of Products by Stage and Mechanism of Action, H2 2015 124 Number of Products by Stage and Route of Administration, H2 2015 129 Number of Products by Stage and Molecule Type, H2 2015 131 Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2015 395 Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H2 2015 593 Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..1), H2 2015 594 Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..2), H2 2015 595 Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..3), H2 2015 596 Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H2 2015 597 Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products (Contd..1), H2 2015 598
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
